Literature DB >> 20619223

Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression.

Iris Barshack1, Eti Meiri, Shai Rosenwald, Danit Lebanony, Meital Bronfeld, Sarit Aviel-Ronen, Kinneret Rosenblatt, Sylvie Polak-Charcon, Ilit Leizerman, Meital Ezagouri, Merav Zepeniuk, Norberto Shabes, Lahav Cohen, Sarit Tabak, Dalia Cohen, Zvi Bentwich, Nitzan Rosenfeld.   

Abstract

Distinguishing hepatocellular carcinoma from metastatic tumors in the liver is of great practical importance, with significant therapeutic and prognostic implications. This differential diagnosis can be difficult because metastatic cancers in the liver, especially adenocarcinomas, may mimic the morphology and immunoexpression of hepatocellular carcinoma. Biomarkers that are specifically expressed in either hepatocellular carcinoma or metastatic adenocarcinoma can therefore be useful diagnostic tools. To find such biomarkers, we studied microRNA expression in 144 tumor samples using custom microarrays. Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors. In contrast, endothelial-associated hsa-miR-126 showed higher expression levels in hepatocellular carcinomas. Combinations of these microRNAs accurately identified primary hepatocellular carcinoma from metastatic adenocarcinoma in the liver. These findings were validated using quantitative real-time PCR to measure microRNA expression in additional samples. Thus, the tissue-specific expression patterns of microRNAs make them useful biomarkers for the diagnosis of liver malignancies. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20619223     DOI: 10.1016/j.biocel.2009.02.021

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  19 in total

1.  Accurate molecular classification of renal tumors using microRNA expression.

Authors:  Eddie Fridman; Zohar Dotan; Iris Barshack; Miriam Ben David; Avital Dov; Sarit Tabak; Orit Zion; Sima Benjamin; Hila Benjamin; Hagit Kuker; Camila Avivi; Kinneret Rosenblatt; Sylvie Polak-Charcon; Jacob Ramon; Nitzan Rosenfeld; Yael Spector
Journal:  J Mol Diagn       Date:  2010-07-01       Impact factor: 5.568

2.  Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma.

Authors:  Hao Gu; Xiaodong Guo; Lin Zou; Haiyan Zhu; Jinhui Zhang
Journal:  Mol Cell Biochem       Date:  2013-01-06       Impact factor: 3.396

3.  MicroRNA-126 deficiency enhanced the activation and function of CD4+ T cells by elevating IRS-1 pathway.

Authors:  F Chu; Y Hu; Y Zhou; M Guo; J Lu; W Zheng; H Xu; J Zhao; L Xu
Journal:  Clin Exp Immunol       Date:  2017-10-30       Impact factor: 4.330

4.  Long non-coding RNA LNC01133 promotes the tumorigenesis of ovarian cancer by sponging miR-126.

Authors:  Bing Hou; Xiaoling Hou; Hailai Ni
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

Review 5.  MicroRNAs in brain metastases: big things come in small packages.

Authors:  Ryan McDermott; Patrik Gabikian; Purvaba Sarvaiya; Ilya Ulasov; Maciej S Lesniak
Journal:  J Mol Med (Berl)       Date:  2012-11-09       Impact factor: 4.599

6.  Clinical value of microRNA-23a upregulation in non-small cell lung cancer.

Authors:  Wei-Qing Qu; Lei Liu; Zhe Yu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 7.  Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis.

Authors:  Jie Bu; Hui Li; Xiao-yang Li; Li-hong Liu; Wei Sun; Tao Xiao
Journal:  Dis Markers       Date:  2015-08-17       Impact factor: 3.434

Review 8.  Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

Authors:  Elisa Callegari; Bahaeldin K Elamin; Silvia Sabbioni; Laura Gramantieri; Massimo Negrini
Journal:  Onco Targets Ther       Date:  2013-09-02       Impact factor: 4.147

9.  Stage and tissue-specific prognostic impact of miR-182 in NSCLC.

Authors:  Helge Stenvold; Tom Donnem; Sigve Andersen; Samer Al-Saad; Lill-Tove Busund; Roy M Bremnes
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

10.  MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1.

Authors:  Ying Liu; Yi Ding; Jing Huang; Shuang Wang; Wen Ni; Jian Guan; Qisheng Li; Yuqin Zhang; Yanqing Ding; Bin Chen; Longhua Chen
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.